Technical Analysis for HTGC - Hercules Technology Growth Capital, Inc.

Grade Last Price % Change Price Change
A 17.37 0.29% 0.05
HTGC closed up 0.29 percent on Wednesday, July 28, 2021, on 79 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical HTGC trend table...

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Earnings Movers Other 0.00%
BB Squeeze Ended Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish 0.29%
50 DMA Support Bullish 0.29%
MACD Bullish Centerline Cross Bullish 0.29%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.29%
Older End-of-Day Signals for HTGC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Upper Bollinger Band Resistance about 13 hours ago
60 Minute Opening Range Breakout about 13 hours ago
Rose Above Upper Bollinger Band about 13 hours ago
Possible NR7 about 14 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Hercules Technology Growth Capital, Inc. Description

Hercules Technology Growth Capital, Inc. is a private equity, venture capital, and venture debt firm specializing in providing debt and equity to privately held venture capital and private equity backed companies and select publicly-traded companies. It offers growth and emerging growth capital and structured debt financing to companies at all stages of development and specializes in venture debt in the forms of senior secured and subordinated working capital loans, senior revolving loans and bridge loans, venture leasing, and select direct equity capital. The firm also provides private equity financing for recapitalizations, leveraged buyouts, spin-off transactions, mergers and acquisitions, public to private financings, and PIPEs. It invests in debt and equity investments in later stage, venture, and lower middle market companies. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. It primarily provides senior secured revolvers and term loans; Unitranche and "one-stop" financings; and mezzanine debt, including "last-out" and second lien financings. The firm typically provides non-control financing solutions used for refinancing of existing indebtedness; acquisition financing – control buyouts and minority recaps; dividend recaps; and growth capital. It prefers to invest in technology, energy technology, health care, life sciences, business services, and manufacturing sectors. Within technology, the firm seeks companies characterized by products or services that require advanced technologies, including communications and telecommunications infrastructure, computing and storage infrastructure, digital media and consumer Internet, e-commerce, enterprise software and services, mobility, networking systems, security, semiconductors components, clean technology, and technology enabled services. Within energy technology, it invests in advanced materials (bio-chemicals, solar materials), carbon (capture, conversion, and abatement), energy efficiency technologies (smart grid, demand response, and lighting), generation (solar, biofuels, and wind), recycling (conversion, diversion, and programs), storage (batteries, fuel cells), technology (management, measurement, controls), transportation (engine design, infrastructure), waste, agriculture, and water (treatment, waste water, and desalination). Within life sciences, the firm invests in biotechnology (including diagnostics), drug discovery and drug delivery, healthcare services, life sciences instrumentation, medical devices, health care services, and specialty pharmaceuticals. It provides growth capital financing solutions with a focus on buy-out or spin-out financing solutions; cash flow based customized financing solutions; company, asset specific, or intellectual property acquisition; convertible, subordinated and/or mezzanine loans; domestic or international expansion; growth capital term loans; vendor financing; established stages of development; and venture debt, asset-based financings with a focus on cash flow-based customized financing solutions; domestic and international account receivable credit lines or revolvers; equipment and infrastructure financing; equipment leases; and facilities build-out and/or expansion. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition with a focus on dividend recapitalizations and other sources of investor liquidity; IPO financing; and merger and acquisition financing. It also provides seed and early-stage financing. It provides specialized energy technology industry financings with a focus on international special purpose entity (SPE) financing; pilot and production facility financing; pre-commercialization facility financing; situation-specific financing (satisfying customer contract requirements, pre-funding strategic relationship, etc.); and supplemental joint venture financing. The firm provides short-term bridge financing. It also provides asset-based financing with a focus on cleantech lab/testing facilities initial build-out and/or expansion; domestic and international working capital revolving lines of credit; equipment loans/leases; inventory build-out; manufacturing capacity expansion. Within life sciences, it provided growth capital financing solutions with a focus on royalty-based financing of existing or future new drugs or medical devices. The firm also provides asset-based financing with a focus on equipment leases and loans; facilities build-out and/or expansion (lab, manufacturing capacity, inventory, etc.). The firm also considers investment in the Mid-Atlantic regions particularly in the areas of software, biotech and information services. It seeks to invest in companies with capital needs from $5 million to $30 million and revenues of $10 million to $200 million, generating EBITDA of $2 million to $15 million, focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm provided loans in the range of $1 million and $30 million and can underwrite transactions up to $40 million. It seeks to provide emerging growth capital with focus on first institutional round (Series A/B). The firm also invests in expansion stage with focus on follow-on rounds of growth capital (Series B-F). It also co-invests with other private equity firms. Hercules Technology Growth Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices across United States.


Sector: Financial Services
Industry: Specialty Finance
Keywords: Private Equity Biotechnology Computing Electronics E-Commerce Pharmaceuticals Batteries Digital Media Semiconductors Drug Discovery Venture Capital Healthcare Services Healthcare Service Recycling Mezzanine Capital Communications Infrastructure Enterprise Software Refinancing Drug Delivery Energy Efficiency Biofuel Private Equity Firms Senior Debt Biofuels Technology Industry Entrepreneurship Fuel Cell Telecommunications Infrastructure Energy Technology Health Care Services Fuel Cells Leveraged Buyout Debt Financing Clean Technology Technology Acquisition Advanced Materials Smart Grid Bridge Financing Venture Debt Consumer Internet Desalination Orix Usa Storage Infrastructure Growth Capital Financing Solutions Manufacturing Sectors Revolver

Is HTGC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.72
52 Week Low 10.75
Average Volume 598,023
200-Day Moving Average 15.41
50-Day Moving Average 17.17
20-Day Moving Average 17.18
10-Day Moving Average 17.16
Average True Range 0.22
ADX 18.23
+DI 19.67
-DI 24.86
Chandelier Exit (Long, 3 ATRs) 16.78
Chandelier Exit (Short, 3 ATRs) 17.33
Upper Bollinger Bands 17.42
Lower Bollinger Band 16.94
Percent B (%b) 0.9
BandWidth 2.78
MACD Line 0.02
MACD Signal Line 0.00
MACD Histogram 0.0219
Fundamentals Value
Market Cap 1.99 Billion
Num Shares 115 Million
EPS 1.08
Price-to-Earnings (P/E) Ratio 16.04
Price-to-Sales 8.41
Price-to-Book 1.36
PEG Ratio 2.19
Dividend 1.28
Dividend Yield 7.37%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.66
Resistance 3 (R3) 17.65 17.55 17.61
Resistance 2 (R2) 17.55 17.48 17.55 17.59
Resistance 1 (R1) 17.46 17.43 17.51 17.47 17.58
Pivot Point 17.36 17.36 17.38 17.36 17.36
Support 1 (S1) 17.27 17.29 17.32 17.28 17.16
Support 2 (S2) 17.17 17.24 17.17 17.15
Support 3 (S3) 17.08 17.17 17.13
Support 4 (S4) 17.09